$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-K Financial Statement

#000143774921022693 Filed on September 27, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2021 Q1
Revenue	$2.564M	$2.710M	$2.600M
YoY Change	7.55%	18.91%	-9.72%
Cost Of Revenue	$1.535M	$1.364M	$1.238M
YoY Change	34.89%	12.91%	5.45%
Gross Profit	$1.029M	$1.346M	$1.362M
YoY Change	-17.42%	25.68%	-20.16%
Gross Profit Margin	40.13%	49.67%	52.38%
Selling, General & Admin	$2.601M	$1.971M	$1.764M
YoY Change	57.83%	1.7%	-10.0%
% of Gross Profit	252.77%	146.43%	129.52%
Research & Development	$702.0K	$468.0K	$362.0K
YoY Change	125.0%	45.34%	23.13%
% of Gross Profit	68.22%	34.77%	26.58%
Depreciation & Amortization	$59.00K	$51.00K	$45.00K
YoY Change	73.53%	18.6%	0.0%
% of Gross Profit	5.73%	3.79%	3.3%
Operating Expenses	$3.303M	$2.439M	$2.128M
YoY Change	68.52%	7.92%	-5.59%
Operating Profit	-$2.274M	-$1.093M	-$766.0K
YoY Change	218.49%	-8.07%	39.78%
Interest Expense	$31.00K	$32.00K	$21.00K
YoY Change	3000.0%	3100.0%	600.0%
% of Operating Profit
Other Income/Expense, Net	$31.00K		$21.00K
YoY Change	3000.0%		600.0%
Pretax Income	-$2.243M	-$1.061M	-$745.0K
YoY Change	214.59%	-10.69%	36.7%
Income Tax
% Of Pretax Income
Net Earnings	-$2.243M	-$1.061M	-$745.0K
YoY Change	214.59%	-10.69%	36.7%
Net Earnings / Revenue	-87.48%	-39.15%	-28.65%
Basic Earnings Per Share	-$0.02	-$0.01	-$0.01
Diluted Earnings Per Share	-$15.81K	-$7.496K	-$6.078K
COMMON SHARES
Basic Shares Outstanding	141.9M	141.5M	122.6M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q3	2021 Q2	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$61.69M	$63.83M	$64.84M
YoY Change	3079.9%	2568.39%	2596.09%
Cash & Equivalents	$61.69M	$63.83M	$64.84M
Short-Term Investments
Other Short-Term Assets	$306.0K	$27.00K	$483.0K
YoY Change	-24.82%	0.0%	-17.72%
Inventory	$1.060M	$980.0K	$731.0K
Prepaid Expenses
Receivables	$1.902M	$2.013M	$2.019M
Other Receivables	$0.00	$32.00K	$0.00
Total Short-Term Assets	$64.96M	$67.30M	$68.07M
YoY Change	1268.69%	1122.12%	1090.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.953M	$1.958M	$1.885M
YoY Change	7.66%	12.85%	8.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$120.0K	$130.0K	$117.0K
YoY Change	-6.25%	-5.8%	-12.03%
Total Long-Term Assets	$3.752M	$3.114M	$3.206M
YoY Change	14.43%	-2.44%	-1.14%
TOTAL ASSETS
Total Short-Term Assets	$64.96M	$67.30M	$68.07M
Total Long-Term Assets	$3.752M	$3.114M	$3.206M
Total Assets	$68.71M	$70.42M	$71.28M
YoY Change	756.2%	709.47%	695.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$768.0K	$730.0K	$992.0K
YoY Change	1.32%	11.62%	5.87%
Accrued Expenses	$1.031M	$1.071M	$924.0K
YoY Change	34.95%	16.29%	14.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.799M	$1.801M	$1.916M
YoY Change	18.2%	14.35%	9.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.152M	$1.209M	$1.266M
YoY Change	-18.18%	-13.7%	-9.57%
Total Long-Term Liabilities	$1.152M	$1.209M	$1.266M
YoY Change	-18.18%	-13.7%	-9.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.799M	$1.801M	$1.916M
Total Long-Term Liabilities	$1.152M	$1.209M	$1.266M
Total Liabilities	$2.951M	$3.010M	$3.182M
YoY Change	0.72%	1.14%	1.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.57M	-$91.33M	-$90.26M
YoY Change	5.55%	3.85%	4.05%
Common Stock	$159.3M	$158.7M	$158.4M
YoY Change	69.96%	69.47%	71.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$65.76M	$67.41M	$68.10M
YoY Change
Total Liabilities & Shareholders Equity	$68.71M	$70.42M	$71.28M
YoY Change	756.2%	709.47%	695.36%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2021 Q1
OPERATING ACTIVITIES
Net Income	-$2.243M	-$1.061M	-$745.0K
YoY Change	214.59%	-10.69%	36.7%
Depreciation, Depletion And Amortization	$59.00K	$51.00K	$45.00K
YoY Change	73.53%	18.6%	0.0%
Cash From Operating Activities	-$2.084M	-$1.118M	-$621.0K
YoY Change	516.57%	31.84%	-27.96%
INVESTING ACTIVITIES
Capital Expenditures	$54.00K	-$138.0K	-$100.0K
YoY Change	-52.21%	253.85%	127.27%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$1.000K
YoY Change
Cash From Investing Activities	-$54.00K	-$138.0K	-$99.00K
YoY Change	-52.21%	253.85%	125.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$51.75M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	243.0K	55.98M
YoY Change		-72.2%	42629.77%
NET CHANGE
Cash From Operating Activities	-$2.084M	-1.118M	-621.0K
Cash From Investing Activities	-$54.00K	-138.0K	-99.00K
Cash From Financing Activities	$0.00	243.0K	55.98M
Net Change In Cash	-$2.138M	-1.013M	55.26M
YoY Change	374.06%	7692.31%	-7229.81%
FREE CASH FLOW
Cash From Operating Activities	-$2.084M	-$1.118M	-$621.0K
Capital Expenditures	$54.00K	-$138.0K	-$100.0K
Free Cash Flow	-$2.138M	-$980.0K	-$521.0K
YoY Change	374.06%	21.14%	-36.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	141915266
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q4	dei	Entity Public Float EntityPublicFloat	38730949
CY2021	dei	Entity Registrant Name EntityRegistrantName	IsoRay, Inc.
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2021	dei	Trading Symbol TradingSymbol	isr
CY2021Q2	isr	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	362000
CY2020Q2	isr	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	352000
CY2021Q2	isr	Accrued Payroll And Related Taxes Noncurrent AccruedPayrollAndRelatedTaxesNoncurrent	77000
CY2020Q2	isr	Accrued Payroll And Related Taxes Noncurrent AccruedPayrollAndRelatedTaxesNoncurrent	55000
CY2019Q3	isr	Aro Discount Amount Interest Rate AroDiscountAmountInterestRate	0.051
CY2019Q3	isr	Aro Original Obligation Amount AroOriginalObligationAmount	704000
CY2019Q3	isr	Asset Retirement Obligation After Adjustment AssetRetirementObligationAfterAdjustment	555000
CY2021	isr	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised	0.63
CY2021	isr	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired	0.54
CY2019	isr	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued	0.76
CY2021	isr	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued	0.57
CY2021	isr	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	12318877
CY2021	isr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	250000
CY2020	isr	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	0
CY2021	isr	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	9134615
CY2019	isr	Class Of Warrant Or Right Issued For Services ClassOfWarrantOrRightIssuedForServices	5830000
CY2021	isr	Class Of Warrant Or Right Issued For Services ClassOfWarrantOrRightIssuedForServices	9134615
CY2021	isr	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1
CY2019Q3	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	73000
CY2021	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate
CY2020	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	73000
CY2019	isr	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate
CY2021	isr	Income Tax Reconciliation Change In Estimate IncomeTaxReconciliationChangeInEstimate	28000
CY2020	isr	Income Tax Reconciliation Change In Estimate IncomeTaxReconciliationChangeInEstimate	-58000
CY2019	isr	Income Tax Reconciliation Change In Estimate IncomeTaxReconciliationChangeInEstimate	-178000
CY2021	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	32000
CY2020	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	318000
CY2019	isr	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	-66000
CY2021	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	63000
CY2020	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	-98000
CY2019	isr	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	56000
CY2021	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	55000
CY2020	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	62000
CY2019	isr	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-33000
CY2020Q1	isr	Maximum Amount Of Equity Securities That Could Be Registered MaximumAmountOfEquitySecuritiesThatCouldBeRegistered	80000000
CY2021	isr	Noncash Expense Lease NoncashExpenseLease	4000
CY2020	isr	Noncash Expense Lease NoncashExpenseLease	4000
CY2019	isr	Noncash Expense Lease NoncashExpenseLease
CY2021	isr	Noncash Financing Activities Warrants Issued NoncashFinancingActivitiesWarrantsIssued
CY2020	isr	Noncash Financing Activities Warrants Issued NoncashFinancingActivitiesWarrantsIssued
CY2019	isr	Noncash Financing Activities Warrants Issued NoncashFinancingActivitiesWarrantsIssued	163000
CY2021Q2	isr	Operating Loss Carryforwards With No Expiration OperatingLossCarryforwardsWithNoExpiration	11400000
CY2020Q4	isr	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	8471000
CY2021Q1	isr	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	47904000
CY2021	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
CY2020	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement
CY2019	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement	45000
CY2021	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	1427000
CY2020	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	1126000
CY2019	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	1429000
CY2021Q2	isr	Restocking Fee Percentage RestockingFeePercentage	0.5
CY2021	isr	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	7784000
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	730000
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	654000
CY2021Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	98000
CY2020Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	35000
CY2021Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	259000
CY2020Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	204000
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7248000
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7517000
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	158589000
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	93592000
CY2021	us-gaap	Adjustment For Amortization AdjustmentForAmortization	37000
CY2020	us-gaap	Adjustment For Amortization AdjustmentForAmortization	38000
CY2019	us-gaap	Adjustment For Amortization AdjustmentForAmortization	50000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	11000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	11000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	9000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	420000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	495000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	386000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	386000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	495000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	420000
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	26000
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	26000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7160398
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11636570
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10784380
CY2020Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	577000
CY2019Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	621000
CY2021Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	608000
CY2021	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	31000
CY2020	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	29000
CY2019	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	31000
CY2021Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	608000
CY2020Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	577000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	50000
CY2021Q2	us-gaap	Assets Assets	70416000
CY2020Q2	us-gaap	Assets Assets	8699000
CY2021Q2	us-gaap	Assets Current AssetsCurrent	67302000
CY2020Q2	us-gaap	Assets Current AssetsCurrent	5507000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63828000
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2392000
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5326000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2573000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5507000
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2781000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	64010000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	61437000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2934000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2726000
CY2018Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.54
CY2019Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.70
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	250000
CY2019Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6080000
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6080000
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2645738
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141915266
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68897779
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141915266
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68897779
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	142000
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	69000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4932000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4556000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4267000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	563000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	682000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations	128000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations	121000
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17646000
CY2020Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16987000
CY2021Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2020Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16568000
CY2020Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15799000
CY2021Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6000
CY2020Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6000
CY2021Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	55000
CY2020Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	124000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	277000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	218000
CY2021Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	49000
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	37000
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17646000
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16987000
CY2021	us-gaap	Depreciation Depreciation	149000
CY2020	us-gaap	Depreciation Depreciation	147000
CY2019	us-gaap	Depreciation Depreciation	136000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	519000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y47D
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	858000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	834000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	10000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	42000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	10000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	21000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	23000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	24000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	988000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	972000
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	130000
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	138000
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-9000
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	24000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-10000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	24000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4691000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4571000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4172000
CY2021	us-gaap	Gross Profit GrossProfit	5121000
CY2020	us-gaap	Gross Profit GrossProfit	5124000
CY2019	us-gaap	Gross Profit GrossProfit	3047000
CY2020Q3	us-gaap	Gross Profit GrossProfit	1246000
CY2020Q4	us-gaap	Gross Profit GrossProfit	1167000
CY2021Q1	us-gaap	Gross Profit GrossProfit	1362000
CY2021Q2	us-gaap	Gross Profit GrossProfit	1346000
CY2019Q3	us-gaap	Gross Profit GrossProfit	1236000
CY2019Q4	us-gaap	Gross Profit GrossProfit	1111000
CY2020Q1	us-gaap	Gross Profit GrossProfit	1706000
CY2020Q2	us-gaap	Gross Profit GrossProfit	1071000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	659000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	739000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1228000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-711000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-724000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1080000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	6000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	8000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	12000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	22000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	24000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	18000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	48000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	52000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-11000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	76000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-29000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-708000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-31000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	890000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-38000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	274000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	97000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-128000
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	6000
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	20000
CY2019	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	37000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	56000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	121000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-30000
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	49000
CY2020Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	23000
CY2021Q2	us-gaap	Inventory Net InventoryNet	980000
CY2020Q2	us-gaap	Inventory Net InventoryNet	645000
CY2021Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	76000
CY2020Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	137000
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	645000
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	401000
CY2021Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	286000
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	221000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	59000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	30000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	108000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	848000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	292000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	264000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	292000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	72000
CY2019Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q2	us-gaap	Liabilities Liabilities	3010000
CY2020Q2	us-gaap	Liabilities Liabilities	2976000
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1801000
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1575000
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	84000
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	141000
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	210000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	994000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7374000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-410000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-287000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	401000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2837000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3641000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5049000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3387000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Organization</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Isoray, Inc. was incorporated in Minnesota in <div style="display: inline; font-style: italic; font: inherit;">1983.</div> On <div style="display: inline; font-style: italic; font: inherit;"> July 28, 2005, </div>Isoray Medical, Inc. (Medical) became a wholly-owned subsidiary of Isoray, Inc. (formerly known as Century Park Pictures Corporation) pursuant to a merger. In <div style="display: inline; font-style: italic; font: inherit;"> December 2018, </div>upon approval of a majority of stockholders, Isoray, Inc. was redomiciled to Delaware. Medical was formed under Delaware law on <div style="display: inline; font-style: italic; font: inherit;"> June 15, 2004 </div>and on <div style="display: inline; font-style: italic; font: inherit;"> October 1, 2004 </div>acquired <div style="display: inline; font-style: italic; font: inherit;">two</div> affiliated predecessor companies which began operations in <div style="display: inline; font-style: italic; font: inherit;">1998.</div> Medical, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Isoray International LLC (International), a Washington limited liability company, was formed on <div style="display: inline; font-style: italic; font: inherit;"> November 27, 2007 </div>and is a wholly-owned subsidiary of Isoray, Inc. International has entered into various international distribution agreements.</div></div>
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	64684000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3446000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-5144000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-713000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-868000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-745000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1061000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-816000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-897000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-545000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1188000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3390000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3457000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5155000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	59000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	30000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	110000
CY2021	us-gaap	Open Tax Year OpenTaxYear	2019 2020 2021
CY2021	us-gaap	Operating Expenses OperatingExpenses	8567000
CY2020	us-gaap	Operating Expenses OperatingExpenses	8600000
CY2019	us-gaap	Operating Expenses OperatingExpenses	8301000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3446000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-3476000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-5254000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	304000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	294000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	285000
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	776000
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	252000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	236000
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	524000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	769000
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	768000
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1001000
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y292D
CY2021Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	67500000
CY2021Q2	us-gaap	Other Assets Current OtherAssetsCurrent	27000
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	27000
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	138000
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	100000
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	94000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000
CY2021Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	315000
CY2020Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	273000
CY2021Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	32000
CY2020Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	31000
CY2021	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	9000
CY2020	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000
CY2019	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	30000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	381000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	273000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	444000
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4725000
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	3000
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11000
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11000
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	21000
CY2020Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	14000
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	481000
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	426000
CY2021Q2	us-gaap	Prepaid Insurance PrepaidInsurance	107000
CY2020Q2	us-gaap	Prepaid Insurance PrepaidInsurance	95000
CY2020Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9500000
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51750000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	34000
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments
CY2020	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments
CY2019	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5550000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	534000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	131000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7784000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9206000
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9252000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1958000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1735000
CY2021Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	2013000
CY2020Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	2044000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1427000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1126000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1474000
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	182000
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91325000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87938000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10053000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.07
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9680000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7314000
CY2020Q3	us-gaap	Revenues Revenues	2384000
CY2020Q4	us-gaap	Revenues Revenues	2359000
CY2021Q1	us-gaap	Revenues Revenues	2600000
CY2021Q2	us-gaap	Revenues Revenues	2710000
CY2019Q3	us-gaap	Revenues Revenues	2315000
CY2019Q4	us-gaap	Revenues Revenues	2206000
CY2020Q1	us-gaap	Revenues Revenues	2880000
CY2020Q2	us-gaap	Revenues Revenues	2279000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1228000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2440000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2976000
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2679000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	386000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	495000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	420000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3443826
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.66
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	770000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	83000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	242000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	192810
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	149405
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	68125
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	22500
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	263125
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.62
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.67
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.54
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.42
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1252500
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1330000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	400000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.86
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.39
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.31
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	49000
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1000
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	233000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	984000
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3759840
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4645315
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5497505
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4514660
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.69
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.64
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	984000
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4514660
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.67
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	400000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1330000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1252500
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.26
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.49
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.55
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.41
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	1.33
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.53
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.44
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.61
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	793000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y273D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y273D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y346D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y310D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y98D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y98D
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.52
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.25
CY2020Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	18269230
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	36000000
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	970315
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	56900
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	262500
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7370000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	874000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	56375000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	131000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	534000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	67406000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5723000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	5030000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	7680000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company's fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company's production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</div></div></div></div></div></div></div>
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	103841000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67601000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67042000
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68898000
CY2020Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83047000
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	122566000
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	141673000
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67388000
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67388000
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67558000
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68075000

Files In Submission

Name	View Source	Status
0001437749-21-022693-index-headers.html	Edgar Link	pending
0001437749-21-022693-index.html	Edgar Link	pending
0001437749-21-022693.txt	Edgar Link	pending
0001437749-21-022693-xbrl.zip	Edgar Link	pending
chart1.jpg	Edgar Link	pending
ex_285363.htm	Edgar Link	pending
ex_285364.htm	Edgar Link	pending
ex_285365.htm	Edgar Link	pending
ex_285366.htm	Edgar Link	pending
ex_285367.htm	Edgar Link	pending
ex_285368.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
isr-20210630.xml	Edgar Link	completed
isr-20210630.xsd	Edgar Link	pending
isr-20210630_cal.xml	Edgar Link	unprocessable
isr-20210630_def.xml	Edgar Link	unprocessable
isr-20210630_lab.xml	Edgar Link	unprocessable
isr-20210630_pre.xml	Edgar Link	unprocessable
isr20210630_10k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2021 Q3 Form 10-K Financial Statement

#000143774921022693 Filed on September 27, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2021 Q3 Form 10-K Financial Statement

#000143774921022693 Filed on September 27, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx